Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

8.48
-0.3350-3.80%
Volume:1.19M
Turnover:10.10M
Market Cap:492.73M
PE:-3.44
High:8.90
Open:8.83
Low:8.38
Close:8.81
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:45.54M
Volume Ratio:0.60
T/O Rate:2.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:2.00
PE(LYR):-3.75

Loading ...

Capricor Therapeutics Shares Fall 68% After US FDA Flags Concerns over Its Duchenne Therapy

THOMSON REUTERS
·
Jul 27

FDA Staff Flags Concerns for Capricor's Duchenne Heart Disease Therapy

Reuters
·
Jul 27

Capricor Therapeutics Shares Fall 60% Premarket After FDA Staff Review Says Data for Co's Duchenne Cell Therapy Does not Provide Substantial Evidence of Effectiveness

THOMSON REUTERS
·
Jul 27

Capricor Therapeutics (CAPR) Secures New Headquarters Tied To FDA Decision On Deramiocel

Simply Wall St.
·
Jul 27

Longeveron Elects Deborah Ascheim to Board of Directors

Reuters
·
Jul 23

Capricor Therapeutics Signs Strategic Headquarters Lease Agreement

TIPRANKS
·
Jul 15

Capricor Therapeutics (CAPR) Stock Looks Overvalued As Its 442% Run Draws Focus

Simply Wall St.
·
Jul 05

Capricor CFO Anthony Bergmann Disposes of USD 732,158 in Common Shares

Reuters
·
Jun 30

Capricor Therapeutics Gets FDA Advisory Panel Meeting for Duchenne Therapy

MT Newswires Live
·
Jun 29

Capricor Therapeutics (CAPR) Is Down 6.8% After Positive Five-Year HOPE-2 DMD Data And FDA Update

Simply Wall St.
·
Jun 28

What's Going On With Capricor Therapeutics Stock On Friday?

Benzinga
·
Jun 27

Capricor Tumbles as FDA Panel Meet for Duchenne Cell Therapy Adds Risk Worries

Reuters
·
Jun 26

Capricor Therapeutics to Face FDA Advisory Panel Review of Deramiocel BLA in Duchenne Muscular Dystrophy

Reuters
·
Jun 26

Capricor announces FDA advisory committee meeting to review Deramiocel BLA

TIPRANKS
·
Jun 26

Capricor Therapeutics Says Deramiocel BLA PDUFA Target Action Date Set for August 22

Reuters
·
Jun 26

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review Bla for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

THOMSON REUTERS
·
Jun 26

Capricor Therapeutics - Deramiocel Bla Pdufa Target Action Date Set for August 22, 2026

THOMSON REUTERS
·
Jun 26

Capricor presents five-year data from HOPE-2 open-label extension study

TIPRANKS
·
Jun 26

Capricor Says Deramiocel Meets Primary Endpoint in Hope-3 Phase 3 Duchenne Muscular Dystrophy Trial

Reuters
·
Jun 26

Capricor Therapeutics EVP, General Counsel Karen Krasney Sells 900 Shares for $27,000

Reuters
·
Jun 25